179 related articles for article (PubMed ID: 8526185)
21. [The chemotherapy of nonseminomatous testicular tumors].
Tiuliandin SA; Bulanov AA; Titov DA; Sokolov AV; Sholokhov VN; Garin AM
Urol Nefrol (Mosk); 1996; (2):26-9. PubMed ID: 8677548
[TBL] [Abstract][Full Text] [Related]
22. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis.
Logothetis CJ; Samuels ML; Selig D; Swanson D; Johnson DE; von Eschenbach AC
J Clin Oncol; 1985 Mar; 3(3):326-35. PubMed ID: 2579213
[TBL] [Abstract][Full Text] [Related]
23. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
[TBL] [Abstract][Full Text] [Related]
24. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
25. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
27. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
28. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
29. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy of testicular cancer: 10-year experience.
Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S
Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
32. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
33. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
34. Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone.
Papadimitris C; Papadimitriou C; Kokolakis N; Athanassiades P; Dimopoulos MA
Urology; 1997 Mar; 49(3):469-70. PubMed ID: 9123720
[TBL] [Abstract][Full Text] [Related]
35. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer.
Pizzocaro G; Salvioni R; Pasi M; Zanoni F; Milani A; Pilotti S; Monfardini S
Cancer; 1985 Jul; 56(2):249-55. PubMed ID: 2408728
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
37. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapeutic and surgical strategies for germ cell tumors.
Einhorn LH
Chest Surg Clin N Am; 2002 Nov; 12(4):695-706. PubMed ID: 12471872
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]